Golden Biotechnology Corporation
Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and … Read more
Golden Biotechnology Corporation (4132) - Total Assets
Latest total assets as of June 2024: NT$577.95 Million TWD
Based on the latest financial reports, Golden Biotechnology Corporation (4132) holds total assets worth NT$577.95 Million TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Golden Biotechnology Corporation - Total Assets Trend (2019–2023)
This chart illustrates how Golden Biotechnology Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Golden Biotechnology Corporation - Asset Composition Analysis
Current Asset Composition (December 2023)
Golden Biotechnology Corporation's total assets of NT$577.95 Million consist of 45.4% current assets and 54.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 29.5% |
| Accounts Receivable | NT$37.37 Million | 5.2% |
| Inventory | NT$75.50 Million | 10.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$27.75 Million | 3.9% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Golden Biotechnology Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Golden Biotechnology Corporation's current assets represent 45.4% of total assets in 2023, an increase from 2.1% in 2019.
- Cash Position: Cash and equivalents constituted 29.5% of total assets in 2023, up from 2.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 5.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 10.6% of total assets.
Golden Biotechnology Corporation Competitors by Total Assets
Key competitors of Golden Biotechnology Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Golden Biotechnology Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Golden Biotechnology Corporation generates 0.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Golden Biotechnology Corporation is currently not profitable relative to its asset base.
Golden Biotechnology Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 1.88 | 2.28 |
| Quick Ratio | 0.41 | 1.58 | 2.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-106.43 Million | NT$ 250.72 Million | NT$ 387.40 Million |
Golden Biotechnology Corporation - Advanced Valuation Insights
This section examines the relationship between Golden Biotechnology Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.02 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -35.3% |
| Total Assets | NT$714.21 Million |
| Market Capitalization | $54.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Golden Biotechnology Corporation's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Golden Biotechnology Corporation's assets decreased by 35.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Golden Biotechnology Corporation (2019–2023)
The table below shows the annual total assets of Golden Biotechnology Corporation from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$714.21 Million | -35.27% |
| 2022-12-31 | NT$1.10 Billion | -25.83% |
| 2021-12-31 | NT$1.49 Billion | +25.58% |
| 2020-12-31 | NT$1.18 Billion | +21.20% |
| 2019-12-31 | NT$977.34 Million | -- |